Table A1.

Distribution of Demographic, Clinical, and Treatment Characteristics of Patients in NSABP Trial B-14 Who Had Assessment of Recurrence Score and Those Who Did Not

Characteristic	Recurrence Score Population in B-14		Remaining B-14 Population		All NSABP B-14 Population
	No.	%	No.	%	No.	%
No. of patients	1,023		3,005		4,028
Treatment enrollment
Placebo	355	35	1,058	35	1,413	35
TAM randomly assigned	290	28	1,114	37	1,404	35
TAM registered	378	37	833	28	1,213	30
Age at enrollment, years
< 50	298	29	947	32	1,245	31
50 ≤ <60	292	29	912	30	1,204	30
≥ 60	433	42	1,146	38	1,579	39
Race
White	933	91	2,711	90	3,644	90
Black	48	5	151	5	199	5
Other	42	4	143	5	185	5
Clinical tumor size, cm
0-1.0	153	15	536	18	689	17
1.1-2.0	448	44	1,347	45	1,795	45
2.1-4.0	369	36	996	33	1,365	34
4.1+	53	5	126	4	179	4
Initial LR treatment
L + XRT	393	38	1,186	39	1,579	39
Mastectomy	630	62	1,819	61	2,449	61

Abbreviations: NSABP, National Surgical Adjuvant Breast and Bowel Project; TAM, tamoxifen; L, lumpectomy; XRT, radiation therapy; LR, locoregional.